Alluvi, previously BI 4744, offers a notable breakthrough in obesity care. This dual stimulator targeting both glucagon-like peptide-1 and GIP targets demonstrates remarkable results in clinical trials, arguably https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/